Here, we used this tracer to monitor the tumor response to the antiangiogenic drug TSU-68, a novel and selective RTK inhibitor of the angiogenic receptors for VEGF, platelet-derived growth factor, and fibroblast growth factor. Here, VEGFA is linked to neoplasm.